procept-biorobotics.com - רווח החברה לפני מסים, ריבית ופחת PRCT

PROCEPT BioRobotics aims to establish Aquablation as the global standard in urology by scaling its expansion. Revenues are driven by the sale of consumables and the growth of the robot install base. Organic development through physician training precludes mergers. Monthly EBITDA dynamics visualize cash flows, where 0.00 shapes the current metric, helping to distinguish seasonal fluctuations from real profit growth.

To protect capital from market volatility, it is crucial for investors to understand the real liquidity of a business, stripped of non-cash accounting adjustments. Stable deliveries of robotic systems and consumables for prostate therapy generate the cash EBITDA, which measures net cash flow from core operations, allowing for an assessment of the operational resilience of PROCEPT BioRobotics (PRCT) and the risk of asset overvaluation.